Is the price fair?
What A's price assumes
Agilent Technologies trades at 32.2× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
32.2
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 4.52
Price / sales · as of 2026-Q2
- Free cash flow yield
- 3.0%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; the business has delivered −2.8% a year over the last three.
Details›
- Price / book2026-Q2
- 4.59
- EV / EBIT2026-Q2
- 21.8
- EV / sales2026-Q2
- 4.69
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $1.09B
- Market capitalisation
- $35.9B
- 3-year revenue growth
- +0.90%
- 3-year free cash flow growth
- −2.8%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $145.77 |
| Its own P/E history, median | $154.60 |
| Its own P/E history, upper quartile | $202.25 |
| 52-week range | $109.99 – $160.00 |
| Today | $160.00 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #16 of 29 by Smart Score